Related Articles
Lumateperone Two New Dosages Approved: 21 mg & 10.5 mg
Lumateperone received its first FDA approval for the management of adult schizophrenia in 2019, and recently FDA has just approved this medication for depressive episodes…
Journal Club #1: Update on Nonpsychotic Unipolar Depression Management
We begin PEFA Journal Club’s updated schedule with our first journal club discussion today: Journal Club #1: The Psychopharmacology Algorithm Project at the Harvard South…
Journal Club #2: Omega-3 Fatty Acids for MDD Treatment (ISNPR Practice Guidelines)
Today we posted the following second journal club in PEFA Journal Club’s discussion series: Journal Club #2: International Society for Nutritional Psychiatry Research Practice Guidelines…
Cariprazine: New FDA Indication for MDD Augmentation
On Dec 16, 2022: AbbVie announced that FDA has approved Cariprazine as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in…
PEFA Journal Club: Updated Schedule Released
Psychiatry Education Forum’s Journal Club is an additional feature for PEF Academy’s members. All academy members will be automatically enrolled in this journal club. Here…